CMS: This year's open enrollment brought fewer signups, higher premiums
fiercehealthcare - The administration's official numbers on the 2026 Open Enrollment Period outlined drops in new customers and automatic re-enrollment, the latter of which CMS said stemmed from its crackdown on improper enrollments. Average monthly premiums also increased …
AI Summary: CMS data show this year's ACA open enrollment produced fewer new signups while benchmark premiums climbed, nudging many consumers into higher‑deductible plans. Enrollment sits near 23.1 million for 2026, but the mix of coverage is tilting toward cost‑sharing over comprehensiveness, raising concerns about affordability and surprising out‑of‑pocket shocks for vulnerable families.
What you should know about the new COVID-19 'Cicada' variant
medicalxpress - A new COVID-19 variant that some have dubbed the "Cicada" variant is quietly spreading across the globe, carrying an unusually high number of mutations that could help it slip past existing immunity, public health experts say. The strain of SARS-CoV-2, ca…
AI Summary: A newly identified SARS‑CoV‑2 lineage nicknamed "Cicada" is showing signs of increased spread, prompting CDC tracking and expert concern. Public health officials advise heightened surveillance, updated testing and genomic sequencing to determine transmissibility, immune escape and clinical impact, while researchers rush to characterize the variant’s risks and inform any needed response.
The new cholesterol guideline: What to know
medicalxpress - For the first time since 2018, a clinical guideline from the American College of Cardiology and the American Heart Association for screening and managing blood cholesterol levels has been updated and jointly published in the Journal of the American Colleg…
AI Summary: Updated cholesterol guidance proposes shifts in testing strategy and risk assessment that may change timing and targets for lipid screening. Clinicians and patients should expect revised thresholds and more personalized testing intervals as the guideline aims to better align prevention with individual cardiovascular risk—so yes, your testing schedule might get a makeover.
- Diet and Upstream Prevention — Community diets and upstream prevention fight heart disease (3)
- OTHER — Triglyceride drug failed to reduce arterial plaque (1)
- Screening and Risk Tools — Earlier screening, personalized risk: guidelines meet AI (3)
- Treatment Advances and Intensive LDL — Aggressive LDL and new drugs reshape prevention strategies (3)
- All Other Stories
Diet and Upstream Prevention — Community diets and upstream prevention fight heart disease
OTHER — Triglyceride drug failed to reduce arterial plaque
Screening and Risk Tools — Earlier screening, personalized risk: guidelines meet AI
Treatment Advances and Intensive LDL — Aggressive LDL and new drugs reshape prevention strategies
All Other Stories
Teens are driving the demand for online abortion pills via telehealth
medicalxpress - Teens in the U.S. are obtaining medication abortion pills through telehealth, and young people aged 18 to 24 are ordering medication abortion at much higher rates than older adults.
AI Summary: Telehealth provision of medication abortion has surged, reducing travel for many and prompting a noticeable uptick in online requests from teenagers. Reports show virtual care is reshaping access patterns and forcing healthcare systems and regulators to confront new realities around remote prescribing, confidentiality, and youth access to reproductive services.
NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC
oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]
AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.
- At ELCC: late‑breaking trials reshaping clinical practice (6)
- OTHER: misc lung oncology studies, regulatory and surgical updates (8)
- Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care (6)
- Voices from ELCC: clinicians share breakthroughs and practical takeaways (17)
- All Other Stories